ESR1 and breast cancer: PGRMC1 facilitates triple-negative breast cancer tumor growth in vivo (14), and in an ER+ human breast cancer cell line that overexpresses PGRMC1, medroxyprogesterone acetate and norethisterone treatment significantly increased proliferation (15, 16).